Free Trial
→ Ticker Revealed: Pre-IPO Access to 'Next Elon Musk' Company (From Banyan Hill Publishing) (Ad)tc pixel
NYSE:ZTS

Zoetis Q3 2026 Earnings Date & Estimates

Zoetis logo
$73.08 +1.53 (+2.13%)
Closing price 10/8/2026 03:59 PM Eastern
Extended Trading
$73.26 +0.19 (+0.25%)
As of 08:05 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Zoetis is scheduled to report Q3 2026 earnings on Thursday, November 5, 2026, before market opens. The conference call is scheduled for 8:30 AM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
Before Market Opens
Conference Call
8:30 AM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Zoetis in Q3 2026

Zoetis is expected to post earnings of $1.52 per share on revenue of $2.30 billion. In the same quarter a year earlier Zoetis reported $1.70 per share on revenue of $2.40 billion. Zoetis last reported on August 6, 2026, posting $1.87 per share and beating the $1.85 consensus estimate. Zoetis has beaten the consensus EPS estimate in 7 of its last 8 quarters.

Consensus Estimates

Consensus EPS
$1.52
Expected Revenue
$2.30 billion
Prior-Year EPS
$1.70
Prior-Year Revenue
$2.40 billion
Expected EPS Growth
-10.6%
Expected Revenue Growth
-4.1%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
$1.87 (Beat by +$0.02)
Last Quarter Revenue
$2.47 billion
EPS Beat Rate
7 of last 8 quarters

Prepare for the Q3 2026 Call

Zoetis Q3 2026 Earnings FAQ

Zoetis (NYSE:ZTS) is scheduled to report Q3 2026 earnings on Thursday, November 5, 2026, before market opens.

Zoetis' Q3 2026 earnings conference call is scheduled for Thursday, November 5, 2026 at 8:30 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Zoetis to post earnings of $1.52 per share for Q3 2026.

The consensus revenue estimate for Zoetis is $2.30 billion for Q3 2026.

Zoetis Earnings Headlines

Zoetis (ZTS) Says Study Shows Simparica Trio Outperformed A Rival On Resistant Heartworm
October 8 at 6:55 PM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/zoetis-zts-says-study-shows-180839914.html
Zoetis Declares Fourth-Quarter Dividend, Signals Ongoing Strength
October 8 at 5:10 PM  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/zoetis-declares-fourth-quarter-dividend-signals-ongoing-strength?utm_source=marketbeat.com&utm_medium=referral
Ticker Revealed: Pre-IPO Access to "Next Elon Musk" Company
We’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billion in government contracts. Peter Thiel just bet $1 Billion on it.tc pixel
October 9 at 1:00 AM  |  Banyan Hill Publishing (Ad)
Zoetis Declares Fourth Quarter 2026 Dividend
October 8 at 5:00 PM  |  businesswire.comhttps://www.businesswire.com/news/home/20261008035404/en/Zoetis-Declares-Fourth-Quarter-2026-Dividend/
New Peer-Reviewed Publication on Laboratory Study That Demonstrated Simparica Trio® Protected 3x More Dogs From Infection With a Resistant Heartworm Isolate Than NexGard® Plus1
October 6 at 8:00 AM  |  businesswire.comhttps://www.businesswire.com/news/home/20261005782418/en/New-Peer-Reviewed-Publication-on-Laboratory-Study-That-Demonstrated-Simparica-Trio%C2%AE-Protected-3x-More-Dogs-From-Infection-With-a-Resistant-Heartworm-Isolate-Than-NexGard%C2%AE-Plus1/
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Zoetis (ZTS), Eli Lilly & Co (LLY) and Liquidia Technologies (LQDA)
October 2, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/ZTS/pressreleases/4931636/analysts-opinions-are-mixed-on-these-healthcare-stocks-zoetis-zts-eli-lilly-co-lly-and-liquidia-technologies-lqda/
See More Zoetis Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Zoetis? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Zoetis and other key companies, straight to your email.

About Zoetis

Zoetis (NYSE:ZTS) is a global animal health company that develops, manufactures and commercializes medicines, vaccines, diagnostics and other products for pets and livestock. Its portfolio is designed to help prevent and treat disease, improve animal health and support veterinary care.

The company serves the companion animal market with products for dogs, cats and other pets, including parasiticides, vaccines, dermatology treatments and pain-management therapies. Zoetis also provides animal health products for cattle, swine, poultry, fish and other livestock, along with diagnostic instruments, tests and services used by veterinarians and producers.

Zoetis was established as an independent public company in 2013 after being separated from Pfizer, which had operated the business as Pfizer Animal Health. The company serves customers in markets around the world through its commercial, manufacturing and research operations. Kristin Peck has served as Zoetis' chief executive officer since 2020.

View Zoetis Profile
Earnings Tools